This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Compounds~~ A compound of ~~the~~ formula I



I

in which

R^1, R^2, independently of one another, ~~denotes~~ denote H, A, Hal, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having 3 to 7 C atoms, CF_3, NO_2, CN, C(NH)NOH, ~~or~~ OCF_3, OH, OA, NH_2, NHA, or NA_2,

Q denotes NR^3R^4 or Het,

R^3, R^4 ~~denotes~~ denote H, $(CH_2)_nHet$, $(CH_2)_nAr$, A, cycloalkyl having 3 to 7 C atoms or CF_3,

R^5 denotes A, Ar or Het,

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkoxyalkyl having 2 to 10 C atoms,

Het denotes ~~an organic heteroatom-containing radical, in particular~~ a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more hetero atoms which is unsubstituted or mono- or polysubstituted by A, cycloalkyl having 3 to 7 C atoms, OH, OA, NH_2, NAH, NA_2, NO_2, CN and/or Hal,

Ar denotes an aromatic organic radical, ~~in particular a phenyl radical~~ which is unsubstituted or mono- or polysubstituted by A, ~~and/or~~ Hal, OR^5, OH, $OOCR^5$, $COOR^5$, COOH, $CON(R^5)_2$, CN, NO_2, NH_2, $NHCOR^5$, CF_3, or SO_2CH_3, or denotes a ring structure containing one of the following groups in the ring ~~a ring-containing group~~ $-OCH_2O-$, $-OC(CH_3)_2O$, or $-OCH_2CH_2O-$,

~~N~~ n denotes 0, 1, 2, 3, 4 or 5,

m denotes 1, 2 or 3,

Hal denotes F, Cl, Br or I, and

X denotes N or CH,

~~and salts and solvates, enantiomers, racemates thereof and other mixtures of the enantiomers, in particular physiologically tolerated salts and solvates thereof~~ or a salt, solvate, enantiomer, or racemate thereof or a mixture thereof.

2. (Withdrawn and Currently Amended) ~~Compounds~~ A compound of ~~the~~ formula I according to Claim 1, in which R^1 denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro- , dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl.

3. (Withdrawn and Currently Amended) ~~Compounds~~ A compound of ~~the~~ formula I according to Claim 1, in which R^3 denotes H.

4. (Withdrawn and Currently Amended) ~~Compounds~~ A compound of ~~the~~ formula I according to Claim 1, in which R^4 denotes H.

5. (Withdrawn and Currently Amended) ~~Compounds~~ A compound of ~~the~~ formula I according to Claim 1, in which R^2 denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl.

6. (Withdrawn and Currently Amended) ~~Compounds~~ A compound of ~~the~~ formula I according to Claim 1, in which X has the meaning N.

7. (Currently Amended) ~~Compounds of the formula IA:~~ A compound of formula IA



IA

in which

~~R^1, R^2, R^5 and X have the meanings indicated in Claim 1~~

R^1, R^2, independently of one another, denote H, A, Hal, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having 3 to 7 C atoms, CF_3, NO_2, CN, C(NH)NOH, OCF_3, OH, OA, NH_2, NHA, or NA_2,

R^5 denotes A, Ar or Het,

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkoxyalkyl having 2 to 10 C atoms,

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more hetero atoms which is unsubstituted or mono- or polysubstituted by A, cycloalkyl having 3 to 7 C atoms, OH, OA, NH_2, NAH, NA_2, NO_2, CN and/or Hal,

Ar denotes an aromatic organic radical, which is unsubstituted or mono- or polysubstituted by A, Hal, OR^5, OH, $OOCR^5$, $COOR^5$, COOH, $CON(R^5)_2$, CN, NO_2, NH_2, $NHCOR^5$, CF_3, or SO_2CH_3, or

denotes a ring structure containing one of the following groups in the ring $-OCH_2O-$, $-OC(CH_3)_2O-$, or $-OCH_2CH_2O-$,

Hal denotes F, Cl, Br or I, and

X denotes N or CH,

or a salt, solvate, enantiomer, or racemate thereof or a mixture thereof.

8. (Withdrawn and Currently Amended) ~~Process~~ A process for ~~the preparation of compounds of the~~ preparing a compound of formula IA according to claim 7,



~~in which R^1, R^2, R^5 and X have the meaning indicated in Claim 1~~

~~and salts and solvates thereof, which is characterised in that~~ comprising reacting a compound of ~~the~~ formula II



II

or an acid-addition ~~salts~~ salt thereof

in which

R^1, R^2 and X have the meanings indicated ~~in Claim 1~~ for the compound of formula IA,

~~is reacted~~ with a compound of ~~the~~ formula III



III

in which

R^5 has the meaning indicated ~~in Claim 1~~ for the compound of formula IA,

and/or ~~in that~~

converting a basic compound of ~~the~~ formula IA ~~is converted~~ into one of its salts by treatment with an acid.

9. (Cancelled)

10. (Withdrawn and Currently Amended) ~~Use of the compounds of the formula I according to Claim 1, and salts and solvates thereof, for the preparation of a medicament for~~ A method for the treatment ~~and~~ or prophylaxis of a disease ~~diseases~~ which

can be influenced by the binding of ~~the compounds of the~~ a compound of formula I according to claim 1 to a 5-HT ~~receptors~~ receptor comprising administering to a subject in need thereof an effective amount of a compound of formula I.

11. (Withdrawn and Currently Amended) ~~Use of compounds of the formula I according t Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having~~ A method for antagonizing a 5-HT receptor ~~antagonistic action~~ comprising administering to a subject in need thereof an effective amount of a compound of formula I according to claim 1.

12. (Withdrawn and Currently Amended) ~~Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having~~ A method for antagonizing a 5-HT2A receptor ~~antagonistic action~~ comprising administering to a subject in need thereof an effective amount of a compound of formula I according to claim 1.

13. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition, comprising a ~~characterised by a content of at least one~~ compound ~~of the formula I~~ according to Claim 1 and/or one of its pharmaceutically ~~physiologically~~ acceptable salts and/or one of its solvates and a pharmaceutically acceptable carrier.

14. (Withdrawn and Currently Amended) ~~Process~~ A process for ~~the preparation of~~ preparing a pharmaceutical ~~compositions, characterised in that~~ composition, comprising bringing a compound ~~of the formula I~~ according to Claim 1 and/or one of its pharmaceutically ~~physiologically~~ acceptable salts and/or one of its solvates ~~is converted~~ into a ~~suitable~~ dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

15. (Currently Amended) ~~Use of compounds of the formula according to Claim 1 and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament~~ A method for the prophylaxis and/or treatment of psychoses, a neurological disorder ~~disorders~~, amyotrophic lateral sclerosis, an eating disorder, ~~disorders, such as~~ bulimia, anorexia nervosa, or ~~of~~ premenstrual syndrome and/or for positively influencing

obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound of formula I according to claim 1.

16. (Currently Amended) ~~Compounds of the formula I in which~~ A compound of formula I



I

in which

R^1, R^2, independently of one another, denote H, A, Hal, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having 3 to 7 C atoms, CF_3, NO_2, CN, C(NH)NOH, OCF_3, OH, OA, NH_2, NHA, or NA_2,

Q denotes NR^3R^4 or Het,

R^3, R^4 denote H, $(CH_2)_nHet$, $(CH_2)_nAr$, A, cycloalkyl having 3 to 7 C atoms or CF_3,

R^5 denotes A, Ar or Het,

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkoxyalkyl having 2 to 10 C atoms,

Het denotes one of the following radicals:





Ar denotes an aromatic organic radical, which is unsubstituted or mono- or polysubstituted by A, Hal, OR^5, OH, $OOCR^5$, $COOR^5$, COOH, $CON(R^5)_2$, CN, NO_2, NH_2, $NHCOR^5$, CF_3, or SO_2CH_3, or
denotes a ring structure containing one of the following groups in the ring–OCH_2O-, -$OC(CH_3)_2O$, or -OCH_2CH_2O-,

n denotes 0, 1, 2, 3, 4 or 5,

m denotes 1, 2 or 3,

Hal denotes F, Cl, Br or I, and

X denotes N or CH,

or a salt, solvate, enantiomer, or racemate thereof or a mixture thereof.

17. (New) A compound of formula I according to Claim 1, in which

Ar denotes a phenyl radical which is unsubstituted or substituted by Hal, OH, CN, NO_2, NH_2, $NHCOCH_3$, $COOCH_3$ $CONH_2$ or CF_3.

18. (New) A compound of formula I



I

in which

R^1, R^2, independently of one another, denote H, A, Hal, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having 3 to 7 C atoms, CF_3, NO_2, CN, C(NH)NOH, OCF_3, OH, OA, NH_2, NHA, or NA_2,

Q denotes NR^3R^4 or Het,

R^3, R^4 denote H, $(CH_2)_nHet$, $(CH_2)_nAr$, A, cycloalkyl having 3 to 7 C atoms or CF_3,

R^5 denotes A, Ar or Het,

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkoxyalkyl having 2 to 10 C atoms,

Het denotes one of the following radicals:



	
	
	
	
	
	
	
	
	

	
	
	
	
	
	
	
	
	

	
	
	
	
	
	
	
	



1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 1-(4-ethyl)piperazinyl, 1-(4-cyclopentyl)piperazinyl, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl 1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which is unsubstituted or substituted by one or more CN group, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, or 2- or 3-pyrazinyl,

Ar denotes an aromatic organic radical, which is unsubstituted or mono- or polysubstituted by A, Hal, OR^5, OH, $OOCR^5$, $COOR^5$, COOH, $CON(R^5)_2$, CN, NO_2, NH_2, $NHCOR^5$, CF_3, or SO_2CH_3, or

denotes a ring structure containing one of the following groups in the ring–OCH_2O-, -$OC(CH_3)_2O$, or -OCH_2CH_2O-,

n denotes 0, 1, 2, 3, 4 or 5,

m denotes 1, 2 or 3,

Hal denotes F, Cl, Br or I, and

X denotes N or CH,

or a salt, solvate, enantiomer, or racemate thereof or a mixture thereof.

19. (New) A compound, which is



1-[1-(4-Benzo[1,3]dioxol-5-ylphenyl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]-4-

methylpiperazine

1-[1-Biphenyl-4-yl-3-(2-fluorophenyl)-1H-pyrazol-4-ylmethyl]-4-methylpiperazine

1-[3-Furan-2-yl-1-(4-thiophen-3-ylphenyl)-1H-pyrazol-4-ylmethyl]-4-methylpiperazine

(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)ethylmethylamine

1-[1-(4-Bromophenyl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]-4-methylpiperazine

(3-Furan-2-yl-1-phenyl-1H-pyrazol-4-ylmethyl)methyl-(1-methylpyrrolidin-3-yl)amine



4-[1-Biphenyl-4-yl-3-(2-fluorophenyl)-1H-pyrazol-4-ylmethyl]morpholine

4-(3-Furan-2-yl-1-phenyl-1H-pyrazol-4-ylmethyl)morpholine

[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]methyl-(1-methylpyrrolidin-3-yl)amine

[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]methyl-(1-methylpyrrolidin-3-yl)amine

{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}methyl-(1-methylpyrrolidin-3-yl)amine

1-Cyclopentyl-4-{1-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}piperazine

4-[3-(2-Fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]morpholine

Diethyl-[3-furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]amine

Diethyl-[1-(4'-fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]amine

Diethyl-[1-(3'-fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]amine

1-[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol

(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)dimethylamine

1-(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)pyrrolidin-3-ol

1-(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)-4-methylpiperazine

1-(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)-4-ethylpiperazine

(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)methyl-(1-methylpyrrolidin-3-yl)amine

1-{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}pyrrolidin-3-ol

2-{[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]amino}ethanol

2-{[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]amino}ethanol

1-[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol

1-[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol

[3-(2-Fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]dimethylamine

Ethyl-[3-(2-fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]methylamine

1-[3-(2-Fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]-4-methylpiperazine

1-Ethyl-4-[3-(2-fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]piperazine

[3-(2-Fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]methyl-(1-methylpyrrolidin-3-yl)amine

1-[3-(2-Fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol

1-[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]piperazine

4-[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester

4-{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}piperazine-1-carboxylic acid tert-butyl ester

4-[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester

4-[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester

1-{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}-4-methyl-[1,4]diazepane

4-[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]morpholine

1-[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]-4-methyl-[1,4]diazepane

1-[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]-4-methyl-[1,4]diazepane

4-[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]morpholine

4-[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]morpholine

1-[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]piperazine

1-[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]piperazine

1-{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-

ylmethyl}piperazine

4-{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}morpholine

2-({1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}amino)ethanol

2-{[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]amino}ethanol

4-(3-Furan-2-yl-1-phenyl-1H-pyrazol-4-ylmethyl)piperazine-1-carboxylic acid tert-butyl ester

1-[1-(4-Butylphenyl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol

1-(3-Furan-2-yl-1-phenyl-1H-pyrazol-4-ylmethyl)pyrrolidin-3-ol, or

1-(3-Furan-2-yl-1-phenyl-1H-pyrazol-4-ylmethyl)piperazine,

or a salt thereof.

20. (New) A compound according to claim 1 or a salt thereof.

21. (New) A compound according to claim 7 or a salt thereof.

22. (New) A compound according to claim 16 or a salt thereof.

23. (New) A compound according to claim 18 or a salt thereof.

24. (New) A compound according to claim 19, which is



1-[1-(4-Benzo[1,3]dioxol-5-ylphenyl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]-4-methylpiperazine

1-[1-Biphenyl-4-yl-3-(2-fluorophenyl)-1H-pyrazol-4-ylmethyl]-4-methylpiperazine

1-[3-Furan-2-yl-1-(4-thiophen-3-ylphenyl)-1H-pyrazol-4-ylmethyl]-4-methylpiperazine

(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)ethylmethylamine

1-[1-(4-Bromophenyl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]-4-methylpiperazine

(3-Furan-2-yl-1-phenyl-1H-pyrazol-4-ylmethyl)methyl-(1-methylpyrrolidin-3-yl)amine



4-[1-Biphenyl-4-yl-3-(2-fluorophenyl)-1H-pyrazol-4-ylmethyl]morpholine

4-(3-Furan-2-yl-1-phenyl-1H-pyrazol-4-ylmethyl)morpholine

[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]methyl-(1-methylpyrrolidin-3-yl)amine

[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]methyl-(1-methylpyrrolidin-3-yl)amine

{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}methyl-(1-methylpyrrolidin-3-yl)amine

1-Cyclopentyl-4-{1-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}piperazine

4-[3-(2-Fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]morpholine

Diethyl-[3-furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]amine

Diethyl-[1-(4'-fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]amine

Diethyl-[1-(3'-fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]amine

1-[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol

(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)dimethylamine

1-(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)pyrrolidin-3-ol

1-(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)-4-methylpiperazine

1-(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)-4-ethylpiperazine

(1,3-Diphenyl-1H-pyrazol-4-ylmethyl)methyl-(1-methylpyrrolidin-3-yl)amine

1-{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}pyrrolidin-3-ol

2-{[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]amino}ethanol

2-{[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]amino}ethanol

1-[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol

1-[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol

[3-(2-Fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]dimethylamine

Ethyl-[3-(2-fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]methylamine

1-[3-(2-Fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]-4-methylpiperazine

1-Ethyl-4-[3-(2-fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]piperazine

[3-(2-Fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]methyl-(1-methylpyrrolidin-3-yl)amine

1-[3-(2-Fluorophenyl)-1-phenyl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol

1-[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]piperazine

4-[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester

4-{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}piperazine-1-carboxylic acid tert-butyl ester

4-[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester

4-[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester

1-{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}-4-methyl-[1,4]diazepane

4-[3-Furan-2-yl-1-(4'-methoxybiphenyl-4-yl)-1H-pyrazol-4-ylmethyl]morpholine

1-[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]-4-methyl-[1,4]diazepane

1-[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]-4-methyl-[1,4]diazepane

4-[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]morpholine

4-[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]morpholine

1-[1-(3'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]piperazine

1-[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]piperazine

1-{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}piperazine

4-{1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}morpholine

2-({1-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenyl]-3-furan-2-yl-1H-pyrazol-4-ylmethyl}amino)ethanol

2-{[1-(4'-Fluorobiphenyl-4-yl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]amino}ethanol

4-(3-Furan-2-yl-1-phenyl-1H-pyrazol-4-ylmethyl)piperazine-1-carboxylic acid tert-butyl ester

1-[1-(4-Butylphenyl)-3-furan-2-yl-1H-pyrazol-4-ylmethyl]pyrrolidin-3-ol

1-(3-Furan-2-yl-1-phenyl-1H-pyrazol-4-ylmethyl)pyrrolidin-3-ol, or

1-(3-Furan-2-yl-1-phenyl-1H-pyrazol-4-ylmethyl)piperazine.

25. (New) A compound according to claim 1, wherein

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic organic radical containing one or more hetero atoms which is unsubstituted or mono- or polysubstituted by A, cycloalkyl having 3 to 7 C atoms, OH, OA, NH_2, NAH, NA_2, NO_2, CN and/or Hal.